Expert Interview
Discussing the FDA approval of Daiichi Sankyo's new first-line AML drug, quizartinib with boxed warning for heart disorders
Ticker(s): DSKYFInstitution: Medical College of Wisconsin
- Staff physician at the Medical College of Wisconsin, board certified in Internal Medicine, Hematology, Medical Oncology.
- Currently manages 2 newly diagnosed FLT3-ITD Positive AML patients and is familiar with the results of the QuANTUM-First trial which the FDA based their approval of Vanflyta from
- Extensive experience in Blood Disorders and Lymphatic System Disorders and affiliated with medical facilities Froedtert Hospital and Froedtert Menomonee Falls Hospital.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
